Science

Research

Research-Based, Research-Focused

At our core, we are scientists committed to advancing research that helps bring safer, more efficacious therapeutics and diagnostics to the patients who need them more quickly. As part of that mission, we maintain an active research and publishing program to share insights and information gleaned from our work with our peers.

Below is a list of scientific posters and publications that were either authored by a member of the Antibody Solutions team, contain information about our firm or pertain to services we performed for clients. If you would like a copy of any article or would like to discuss our findings, please don’t hesitate to get in touch with us via email (solutions@antibody.com) or phone (888.843.1069).

Latest Research

• The SARS-CoV-2 Spike Protein D614G Mutation Shows Increasing Dominance and May Confer a Structural Advantage to the Furin Cleavage Domain

  Tang, L.; Schulkins, A.; Chen, C.; Deshayes, K.; Kenney, J.S. The SARS-CoV-2 Spike Protein D614G Mutation Shows Increasing Dominance and May Confer a Structural Advantage to the Furin Cleavage Domain. Preprints 2020, 2020050407 (doi: 10.20944/preprints202005.0407.v1).

Scientific Posters

All scientific posters are available in PDF format. Choose a poster below to download.

• Development of a Defined Cloning and Growth Factor Formulation for Murine Hybridomas
  Liisa Alajoki and John S. Kenney
• Antibody targeting functional domains of the SARS-CoV-2 Spike protein
  John S. Kenney, Kurt DeShayes, Catherine Vo, Emmeline Truong, Rick Chang, Opel Arenas, Shyairra Dodd, Huda Abushanab, Ron Gamatero, Edgar Rodriguez, Glen Lin, Leonel Santibanez-Vargas, Emily Keshner, and Joshua K. Lowitz.
• Generation of Neutralizing Human Monoclonal Antibodies Against a Therapeutic Target from the Alloy Therapeutics Mouse
  Joshua Lowitz, Glen Lin, Avery Van Horn, Jennifer Somera, Ryan Kim, Rick Chang, Catherine Vo, Ronald Gamatero, Opal Arenas, Emmeline Truong, Nicholas Wameling, Birthe Jessen^, Heather Schwoebel, Mike Snaith, and John S. Kenney, Antibody Solutions, Sunnyvale, Calif., USA & Alloy Therapeutics, Hanover, N.H., USA
  
• Generation Using a Molecular Modeling Platform to Guide Therapeutic Antibody Discovery
  Joshua Lowitz, Kurt Deshayes, and John S. Kenney, Antibody Solutions, Santa Clara, Calif., USA
  
• Optimization of Therapeutic Discovery Strategies for Human Antibody Transgenic Animal Platforms
  Joshua Lowitz, Glen Lin, Jennifer Somera, Leonel Santibanez-Vargas, Catherine Vo, Edgar Rodriguez, Billy Nguyen, Michael Trang, John Nichols and John S. Kenney Antibody Solutions, Sunnyvale, CA, USA
  
• Development of Antibody and PK, and ADA Assays for a Cystine Knot Fusion Protein
  Joshua K. Lowitz, Michael Trang, Catherine Vo, Glen Lin, Jennifer Somera, Rick Chang, Shannon Jones-Iatauro, Ronald Gamatero, and John S. Kenney Antibody Solutions, Sunnyvale, CA
  
• A Rapid, High-Throughput Recombinant Antibody Expression System for Therapeutic Antibody Discovery and Validation
  Michael Trang, Leonel Santibanez-Vargas, Keerthi Sindhu, Catherine Vo, Edgar Rodriguez, John Kenney Antibody Solutions, Sunnyvale, CA, USA
  
• Generation of Agonist and Antagonist Human Monoclonal Antibodies Against an Immune Checkpoint Target from the H2L2 Mouse
  Joshua Lowitz, Glen Lin, Rick Chang, Jennifer Somera, Leonel Santibanez-Vargas, Julia Teplyuk, Catherine Vo, Emmeline Truong, Billy Nguyen, Gang Deng^, Yiping Rong^, Jiuqiao Zhao, and John S. Kenney Antibody Solutions, Sunnyvale, CA, USA & Harbour BioMed, Newton, MA, USA
  
• Generation and Selection of Human Monoclonal Antibodies from the OmniRat^TM
  John S. Kenney, Glen Lin, Jennifer Somera, Leonel Santibanez-Vargas, Rick Chang, Joshua Lowitz, Billy Nguyen, Julie Ngo, and Roland Buelow Antibody Solutions, Sunnyvale, CA, USA & Open Monoclonal Technologies (OMT), Palo Alto, CA, USA
  
• Therapeutic Antibody Discovery at Antibody Solutions using the OmniAb^TM Platform
  John S. Kenney, Joshua Lowitz, Glen Lin, Jennifer Somera, Leonel Santibanez-Vargas, Catherine Vo, Spencer Alford*, Ryan Kelly*, and Jennifer Cochran*. Antibody Solutions, Sunnyvale, CA, USA & *xCella Biosciences, Menlo Park, CA, USA
  
• Development of human antibodies to human vascular endothelial growth factor -C (VEGF-C) and -D (VEGF-D)
  John S. Kenney, Joshua K. Lowitz, Billy Nguyen, Julia Cohn, Jennifer Somera, Tapati Das, & Glen Lin Antibody Solutions, Sunnyvale, CA, USA
  
• Obtaining Antibodies to Difficult Membrane Targets through DNA and Cell Immunization
  Joshua K. Lowitz, Glen Lin, Leonel Santibanez-Vargas, Rick Chang, Billy Nguyen, Roland Buelow and John S. Kenney, Antibody Solutions, Sunnyvale, CA, USA & Open Monoclonal Technologies, Palo Alto, CA USA
  
• Next-Generation Therapeutic Antibody Discovery from Single B-cells
  Joshua Lowitz, John S. Kenney, Michael Trang, Glen Lin, Jennifer Somera, Leonel Santibanez-Vargas, Catherine Vo, Allison Schulkins, Joy Tang, Jim Bowlby, Rich Jorgensen and Chun-Nan Chen, Antibody Solutions, Sunnyvale, CA, USA and Single Cell Technology, San Jose, CA USA
  
• Generation and Selection of Human Monoclonal Antibodies from the H2L2 Mouse
  Joshua Lowitz, John S. Kenney, Glen Lin, Rick Chang, Jennifer Somera, Leonel Santibanez-Vargas, Julia Teplyuk, Catherine Vo, Emmeline Truong, Billy Nguyen, Zhiping Yao, Yiping Rong, and Jiuqiao Zhao, Antibody Solutions, Sunnyvale, CA, USA & Harbour BioMed, Newton, MA, USA
  
• Generation of Antibodies to Difficult Membrane Protein Targets
  Joshua K. Lowitz, Glen Lin, Leonel Santibanez-Vargas, Jennifer Somera, Billy Nguyen, and John S. Kenney Antibody Solutions, Sunnyvale, CA, USA
  
• Development of Antibodies and ELISAs to measure Free and Total Obiltoxaximab (ETI-204) in the Presence of Anthrax Protective Antigen PA63
  Joshua K. Lowitz, John P. Nichols, Sarah E. Carpenter, Edward F. O’Connor and John S. Kenney, Antibody Solutions, Elusys Therapeutics, Alexion Pharmaceuticals
  
• Discovery of Therapeutic Antibodies to Difficult Membrane Proteins
  Joshua K. Lowitz, Glen Lin, Leonel Santibanez-Vargas, Jennifer Somera, Billy Nguyen, and John S. Kenney, Antibody Solutions, Sunnyvale, CA, USA, Palo Alto, CA USA
  
• Discovery Platform for Therapeutic D-Proteins
  Joshua K. Lowitz, Billy Nguyen, Glen Lin, Michael Trang, Dana Ault-Riche and John S. Kenney, Antibody Solutions, Sunnyvale, CA, USA & Reflexion Phamaceuticals, San Francisco, CA USA

Select Publications

• Mandal K, Uppalapati M, Ault-Rich D, Kenney J, Lowitz J, Sidhu SS, Kent SB. Chemical synthesis and X-ray structure of a heterochiral {D-protein antagonist plus vascular endothelial growth factor} protein complex by racemic crystallography. Proc Natl Acad Sci USA. 2012 Sep 11;109(37):14779-84.
• O’Hara DM, Theobald V, Egan AC, Usansky J, Krishna M, TerWee J, Maia M, Spriggs FP, Kenney J, Safavi A, Keefe J. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J. 2012 Jun;14(2):316-28.
• McArthur, JG. Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders. US Patent No. 7,972,846 B2. Jul. 5, 2011.
• Rodriguez HM, Vaysberg M, Mikels A, McCauley S, Velayo AC, Garcia C, Smith V. Modulation of Lysyl Oxidase-like 2 Enzymatic Activity by an Allosteric Antibody Inhibitor. J Biol Chem. 2010 Jul 2;285(27):20964-74.
• Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Satyal S, Wang X, Clarke MF, Lewicki J, Gurney A. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell. 2009 Aug 7;5(2):168-77.
• Kochan JP, Burghardt CR, Rasmussen ER. Characterization and identification of unique human adiponectin isoforms and antibodies. US Patent No. 2,009,0123,943. May 14, 2009.
• Rosen SD, Tsay D, Singer MS, Hemmerich S, Abraham WM. Therapeutic targeting of endothelial ligands for L-selectin (PNAd) in a sheep model of asthma. Am J Pathol. 2005 Mar;166(3):935-44.
• Tripathi MK, Misra S, Khedkar SV, Hamilton N, Irvin-Wilson C, Sharan C, Sealy L, Chaudhuri G. Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells. J Biol Chem. 2005 Apr 29;280(17):17163-71.
• Kim Stopak, Carlos de Noronha, Wes Yonemoto, and Warner C. Greene. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both Its translation and intracellular stability. Molecular Cell, Vol. 12, 591:601, September, 2003.
• Hannah M. Lui, Jun Chen, Lingli Wang, and Louie Naumovski. ARMER, Apoptotic regulator in the membrane of the endoplasmic reticulum, a novel inhibitor of apoptosis Molecular Cancer Research, Vol. 1, 508:518, May 2003.
• Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, Whittaker K, Demsky M, Fisher WW, Buchman A, Duyk G, Friedman L, Prives C, Kopczynski C. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell. 2000 Mar 31;101(1):91-101.
• Kenney JS, Gray F, Ancel M-H, Dunne, JF. Production of monoclonal antibodies using a secretion capture report web. 1995 Biotechnology 13:787-790, 1995.
• Gray F, Kenney JS, Dunne, JF. Secretion capture and report web: use of affinity derivatized agarose microdroplets for the selection of hybridoma cells. J. Immunol. Methods 182: 155-163, 1995.
• Kenney JS, Hughes BH, Allison AC. Determination of antibody affinity and concentration by solution-phase micro-radioimmunoassay. In: Zola H. (ed.), Laboratory Methods in Immunology, Vol. 1, CRC Press, Boca Raton, Chap. 17, 1990.
• Kenney JS, Masada MP, Allison AC. Development of quantitative two-site ELISAs for soluble proteins. In: Zola, H. (ed.), Laboratory methods in immunology, Vol. 1, CRC Press, Boca Raton, Chap. 20, 1990.
• Kenney JS, Hughes BW, Masada MP, Allison AC. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Methods 121: 157-166, 1989.